Effect of Prophylactic Tranexamic Acid Administration on Perioperative Bleeding and Thromboembolic Outcomes in Patients Undergoing Bariatric Surgery: A Retrospective Observational Cohort Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 140
- 试验地点
- 1
- 主要终点
- Postoperative Hemoglobin Reduction
研究概览
简要总结
Postoperative bleeding is an important complication of bariatric surgery and may lead to increased morbidity, prolonged hospitalization, and higher healthcare costs. Tranexamic acid (TXA) has been shown to reduce perioperative blood loss in several surgical specialties; however, evidence regarding its effectiveness and safety in bariatric surgery remains limited.
This retrospective observational cohort study aims to evaluate the effect of prophylactic intraoperative tranexamic acid administration on perioperative bleeding in patients undergoing bariatric surgery. The primary objective is to assess the postoperative decrease in hemoglobin levels. Secondary objectives include evaluating the need for blood transfusion, length of hospital stay, and the incidence of thromboembolic complications, including deep vein thrombosis, pulmonary embolism, portal vein thrombosis, and acute coronary syndrome.
The study includes patients who underwent bariatric surgery at G. Gennimatas General Hospital between May 1, 2024, and April 30, 2026.
详细描述
This is a single-center retrospective observational cohort study including patients who underwent bariatric surgery at G. Gennimatas General Hospital between May 1, 2024, and April 30, 2026.
The study compares patients who received prophylactic intraoperative tranexamic acid with those who did not receive tranexamic acid. Demographic characteristics, comorbidities, laboratory findings, perioperative variables, and postoperative outcomes will be collected from medical records.
The primary outcome is the postoperative reduction in hemoglobin concentration following bariatric surgery.
Secondary outcomes include blood transfusion requirements, length of hospital stay, timing and type of postoperative thromboprophylaxis, and thromboembolic complications, including deep vein thrombosis, pulmonary embolism, portal vein thrombosis, and acute coronary syndrome.
Patients with known thrombophilia, coagulation disorders, chronic anticoagulant or antiplatelet therapy, previous pulmonary embolism, coronary artery disease, chronic kidney disease, or hypersensitivity to tranexamic acid will be excluded.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults (≥18 years of age).
- •Patients who underwent bariatric surgery at G. Gennimatas General Hospital between May 1, 2024, and April 30,
- •Availability of complete perioperative and postoperative medical records.
排除标准
- •Known thrombophilia.
- •Coagulation disorders.
- •Chronic anticoagulant or antiplatelet therapy.
- •Previous pulmonary embolism.
- •Coronary artery disease.
- •Chronic kidney disease.
- •Known hypersensitivity to tranexamic acid.
研究组 & 干预措施
Tranexamic Acid Group
Patients undergoing bariatric surgery who received prophylactic intraoperative tranexamic acid as part of routine clinical practice.
Control Group
No Tranexamic Acid Group
结局指标
主要结局
Postoperative Hemoglobin Reduction
时间窗: 48 hours after surgery
Difference between preoperative hemoglobin concentration and postoperative hemoglobin concentration following bariatric surgery, comparing patients who received prophylactic tranexamic acid with those who did not.
次要结局
- Blood Transfusion Requirement(Up to 4 weeks)
- 2. Length of Hospital Stay(Up to 4 weeks)
- Thromboembolic Complications(Up to 4 weeks)
- Postoperative Hemoglobin at 24 Hours(24 hours after surgery)
研究者
Panagiotis Chatzistavridis
Resident anesthesiologist, Department of Anesthesiology, MSC in Clinical Pharmacology
G.Gennimatas General Hospital